AKTS Company Profile and Key Details

Q: Who are the executives of AKTS?

Mr. Andrew WrightGen. Counsel & Corporation Sec.Mr. Jeffrey B. ShealyFounder, Pres, Chief Executive Officer & DirectorMr. Kenneth E. BollerChief Financial Officer & Corporation ControllerMr. Kamran CheemaChief Product OfficerMr. David M. AicheleExecutive Vice President of Bus. Devel.Ms. Mary WintersExecutive Vice President of Fab & Corporation OperationsMr. Thomas Andrew SepenzisVice President of Corporation Devel. & IR

NASDAQ : AKTS

Aktis Oncology

$18.84

-1.19-5.94%

At Close 4:00 PM

61.81

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Aktis Oncology, Inc. (AKTS) stock declined over -5.94%, trading at $18.84 on NASDAQ, down from the previous close of $20.03. The stock opened at $19.98, fluctuating between $18.76 and $20.17 in the recent session.

Stock Snapshot

20.03

Prev. Close

1.01B

Market Cap

18.76

Day Low

-15.57

P/E Ratio

-1.21

EPS (TTM)

-0.72

Cash Flow per Share

19.98

Open

53.4M

Number of Shares

20.165

Day High

97.52%

Free Float in %

0.74

Book Value

171.52K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 07, 2026	19.98	20.17	18.76	18.84	171.52K
May 06, 2026	19.85	20.72	19.68	20.03	163.1K
May 05, 2026	19.01	19.92	18.75	19.44	151.4K
May 04, 2026	19.26	20.24	18.68	19.00	150.82K
Apr 30, 2026	18.54	19.56	18.25	18.75	177.52K
Apr 29, 2026	18.72	18.92	17.98	18.72	250.58K
Apr 28, 2026	19.67	20.09	18.45	18.60	327.86K
Apr 27, 2026	21.02	22.40	19.86	20.09	218.67K
Apr 23, 2026	22.00	22.38	21.00	22.08	270.52K
Apr 22, 2026	20.76	22.00	20.76	22.00	302.73K
Apr 21, 2026	20.93	21.48	19.86	20.50	292.45K
Apr 20, 2026	20.20	21.50	19.55	20.83	196.14K
Apr 17, 2026	19.00	20.40	18.80	20.25	205.25K
Apr 16, 2026	18.20	18.66	17.86	18.60	356.11K
Apr 14, 2026	17.34	18.08	17.32	17.84	213.28K
Apr 13, 2026	16.63	17.43	16.63	17.34	205.37K
Apr 10, 2026	17.76	17.90	16.10	16.88	261.39K
Apr 09, 2026	16.98	17.95	16.77	17.67	292.3K
Apr 08, 2026	17.23	17.34	16.60	16.98	215.38K
Apr 07, 2026	16.20	16.91	15.67	16.72	349.1K

Contact Details

Boston, MA 02210

United States

https://www.aktisoncology.com 617 461 4023

About Company

Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts.

Stock Peers

ARGX

-20.24002-2.51%

argenx SE$787.31 REGN

-11.95-1.66%

Regeneron Pharmaceuticals, Inc.$709.10 UTHR

-27.58-4.62%

United Therapeutics Corporation$569.18 MDGL

-4.87-0.90%

Madrigal Pharmaceuticals, Inc.$534.86 VRTX

-2.65-0.62%

Vertex Pharmaceuticals Incorporated$425.00 PRAX

-4.79-1.42%

Praxis Precision Medicines, Inc.$333.28 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

7.71+2.67%

Krystal Biotech, Inc.$296.70 ALNY

-7.09-2.34%

Alnylam Pharmaceuticals, Inc.$295.91 ASND

10.24+4.34%

Ascendis Pharma A/S$246.14

Frequently Asked Questions

What is the current Aktis Oncology, Inc. (AKTS) stock price?

Aktis Oncology, Inc. (NASDAQ: AKTS) stock price is $18.84 in the last trading session. During the trading session, AKTS stock reached the peak price of $20.17 while $18.76 was the lowest point it dropped to. The percentage change in AKTS stock occurred in the recent session was -5.94% while the dollar amount for the price change in AKTS stock was - $1.19.

AKTS's industry and sector of operation?

The NASDAQ listed AKTS is part of Biotechnology industry that operates in the broader Healthcare sector. Aktis Oncology, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of AKTS?

Mr. Andrew Wright
Gen. Counsel & Corporation Sec.
Mr. Jeffrey B. Shealy
Founder, Pres, Chief Executive Officer & Director
Mr. Kenneth E. Boller
Chief Financial Officer & Corporation Controller
Mr. Kamran Cheema
Chief Product Officer
Mr. David M. Aichele
Executive Vice President of Bus. Devel.
Ms. Mary Winters
Executive Vice President of Fab & Corporation Operations
Mr. Thomas Andrew Sepenzis
Vice President of Corporation Devel. & IR

How AKTS did perform over past 52-week?

AKTS's closing price is 27.99% higher than its 52-week low of $14.72 where as its distance from 52-week high of $29.16 is -35.39%.

How many employees does AKTS have?

Number of AKTS employees currently stands at 0.

Link for AKTS official website?

Official Website of AKTS is: https://www.aktisoncology.com

How do I contact AKTS?

AKTS could be contacted at phone 617 461 4023 and can also be accessed through its website. AKTS operates from 17 Drydock Avenue, Boston, MA 02210, United States.

How many shares of AKTS are traded daily?

AKTS stock volume for the day was 171.52K shares. The average number of AKTS shares traded daily for last 3 months was 339.92K.

What is the market cap of AKTS currently?

The market value of AKTS currently stands at $1.01B with its latest stock price at $18.84 and 53.4M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	0
Beta	0
Sales or Revenue	$27.38M
5Y Sales Change%	6.386%
Fiscal Year Ends	June
Sector	Healthcare
Industry	Biotechnology

Employees	0
Beta	0
Sales or Revenue	$27.38M
5Y Sales Change%	6.386%
Fiscal Year Ends	June
Sector	Healthcare
Industry	Biotechnology

AKTS Company Profile and Key Details

Aktis Oncology

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Company Overview

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook

Valuation Metrics